NCT06413433Phase 3Recruiting

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Study sponsor: Axsome Therapeutics, Inc. · AXSM

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants450Estimated

Source updated2026-07-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-28 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2025-12

+ Updated value

2026-12

Check registry source